Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells

Blood Cells, Molecules, and Diseases

Volumn 52, Issue 2-3, 2014, Pages 126-133

  McCranor, Bryan J ^a   Kim, Min Jung ^b   Cruz, Nicole M ^a   Xue, Qian Li ^a   Berger, Alan E ^a   Walston, Jeremy D ^a   Civin, Curt I ^b   Roy, Cindy N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Cytokine; Erythropoiesis; Hemoglobin; Inflammation; Mitochondria

Indexed keywords

BENZIDINE; CYTOKINE; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; POLYPEPTIDE ANTIBIOTIC AGENT;

ARTICLE; CELL MATURATION; DOWN REGULATION; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; ERYTHROLEUKEMIA CELL; ERYTHROPOIESIS; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN CELL; IRON RESTRICTION; MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL;

AICD; ALAS2; AMINOLEVULINATE SYNTHASE 2; ANEMIA; ANEMIA OF INFLAMMATION OR CHRONIC DISEASE; BAND 3; CHLOROMETHYL-2′,7′-DICHLORODIHYDROFLUORESCEIN DIACETATE, ACETYL ESTER; CM-H(2)DCFDA; CYTOKINE; EPO; ERYTHROPOIESIS; ERYTHROPOIETIN/EPOETIN ALFA; GLYCOPHORIN A; GM-CSF; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GYPA; HBB; HEMOGLOBIN; HEMOGLOBIN BETA; IFN; IL-6; INFLAMMATION; INTERFERON; INTERLEUKIN-6; MITOCHONDRIA; SCF; SERUM FREE EXPANSION MEDIUM; SFEM; SLC4A1; STEM CELL FACTOR; TETRAMETHYLRHODAMINE METHYL ESTER PERCHLORATE; TMRM; TNF; TUMOR NECROSIS FACTOR;

ANTIGENS, SURFACE; CELL LINE, TUMOR; ERYTHROPOIESIS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-6; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; REACTIVE OXYGEN SPECIES;

EID: 84891903512     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.09.004     Document Type: Article

References (84)

1. Weiss G., Goodnough L.T. Anemia of chronic disease. N. Engl. J. Med. 2005, 352:1011-1023.
2. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., Klein H.G., Woodman R.C. Prevalence of anemia in persons 65years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004, 104:2263-2268.
3. Izaks G.J., Westendorp R.G., Knook D.L. The definition of anemia in older persons. JAMA 1999, 281:1714-1717.
4. Nissenson A., Goodnough L., Dubois R. Anemia: not just an innocent bystanderα. JAMA Intern. Med. 2003, 163:1400-1404.
5. Harrison L., Shasha D., Shiaova L., et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin. Oncol. 2001, 28:54-59.
6. Md Yusof M., Emery P. Targeting interleukin-6 in rheumatoid arthritis. Drugs 2013, 73:341-356.
7. Weiss G., Schett G. Anaemia in inflammatory rheumatic diseases. Nat. Rev. Rheumatol. 2013, 9:205-215.
8. Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologistα. Nephrol. Dial. Transplant. 2003, 18(Suppl. 8):viii17-22.
9. Yilmaz M., Solak Y., Covic A., Goldsmith D., Kanbay M. Renal anemia of inflammation: the name is self-explanatory. Blood Purif. 2011, 32:220-225.
10. Sullivan P.S., Hanson D.L., Chu S.Y., Jones J.L., Ward J.W. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998, 91:301-308.
11. Zakai N.A., Katz R., Hirsch C., et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch. Intern. Med. 2005, 165:2214-2220.
12. Milman N., Pedersen A.N., Ovesen L., Schroll M. Hemoglobin concentrations in 358 apparently healthy 80-year-old Danish men and women. Should the reference interval be adjusted for ageα. Aging Clin. Exp. Res. 2008, 20:8-14.
13. Cesari M., Penninx B.W., Lauretani F., et al. Hemoglobin levels and skeletal muscle: results from the InCHIANTI study. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59:249-254.
14. Culleton B.F., Manns B.J., Zhang J., et al. Impact of anemia on hospitalization and mortality in older adults. Blood 2006, 107:3841-3846.
15. Penninx B.W., Pahor M., Woodman R.C., Guralnik J.M. Anemia in old age is associated with increased mortality and hospitalization. J. Gerontol. A Biol. Sci. Med. Sci. 2006, 61:474-479.
16. Arant C., Wessel T., Olson M., et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute Women's Ischemia Syndrome Evaluation Study. J. Am. Coll. Cardiol. 2004, 43:2009-2014.
17. Go A., Yang J., Ackerson L., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure. Circulation 2006, 113:2713-2723.
18. Caro J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001, 91:2214-2221.
19. Chaves P.H., Ashar B., Guralnik J.M., Fried L.P. Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women. Should the criteria currently used to define anemia in older people be reevaluatedα. J. Am. Geriatr. Soc. 2002, 50:1257-1264.
20. Chaves P.H., Carlson M.C., Ferrucci L., et al. Association between mild anemia and executive function impairment in community-dwelling older women: the Women's Health and Aging Study II. J. Am. Geriatr. Soc. 2006, 54:1429-1435.
21. Deal J.A., Carlson M.C., Xue Q.L., Fried L.P., Chaves P.H. Anemia and 9-year domain-specific cognitive decline in community-dwelling older women: the Women's Health and Aging Study II. J. Am. Geriatr. Soc. 2009, 57(9):1604-1611.
22. Cella D., Dobrez D., Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann. Oncol. 2003, 14:511-519.
23. Sabbatini P. The relationship between anemia and quality of life in cancer patients. Oncologist 2000, 5:19-23.
24. Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am. J. Med. 2004, 116:11-26.
25. Price E.A. Aging and erythropoiesis: current state of knowledge. Blood Cells Mol. Dis. 2008, 41:158-165.
26. Artz A., Thirman M. Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66:925-932.
27. Tettamanti M., Lucca U., Gandini F., et al. Prevalence, incidence and types of mild anemia in the elderly: the "Health and Anemia" population-based study. Haematologica 2010, 95:1849-1856.
28. Fontenay M., Cathelin S., Amiot M., Gyan E., Solary E. Mitochondria in hematopoiesis and hematological diseases. Oncogene 2006, 25:4757-4767.
29. Yaun X., Fleming M., Hamza I. Heme transport and erythropoiesis. Curr. Opin. Chem. Biol. 2013, 17:204-211.
30. Chung J., Chen C., Paw B. Heme metabolism and erythropoiesis. Curr. Opin. Hematol. 2012, 19:156-162.
31. Kumari U., Yan Jun W., Huat Bay B., Lyakhovich A. Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi anemia cells. Oncogene 2013, (PMID:23318445).
32. Pagano G., Aiello Talamanca A., Castello G., et al. From clinical description, to in vitro and animal studies, and backward to patients: oxidative stress and mitochondrial dysfunction in Fanconi anemia. Free Radic. Biol. Med. 2013, 58:118-125.
33. Harigae H., Furuyama K. Hereditary sideroblastic anemia: pathophysiology and gene mutations. Int. J. Hematol. 2010, 92:425-431.
34. Chen M., Logan T., Hochberg M., et al. Erythriod dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood 2009, 114:4045-4053.
35. Chen E. Mitochondrial dysfunction and cancer metastasis. J. Bioenerg. Biomembr. 2012, 44:619-622.
36. Moodley D., Mody G., Patel N., Chuturgoon A. Mitochondrial depolarisation and oxidative stress in rheumatoid arthritis patients. Clin. Biochem. 2008, 41:1396-1401.
37. Granata S., Zaza G., Simone S., et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009, 10.
38. Scheibye-Knudsen M., Scheibye-Alsing K., Canugovi C., Croteau D., Bohr V. A novel diagnostic tool reveals mitochondrial pathology in human diseases and aging. Aging (Albany NY) 2013, 5:192-208.
39. Bratic A., Larsson N. The role of mitochondria in aging. J. Clin. Invest. 2013, 123:951-957.
40. Lopez-Armada M., Carames B., Martin M., et al. Mitochondrial activity is modulated by TNFα and IL-1β in normal human chondrocyte cells. Osteoarthr. Cartil. 2006, 14.
41. Stadler J., Bentz B., Harbrecht B., et al. Tumor necrosis factor alpha inhibits hepatocyte mitochondrial respiration. Ann. Surg. 1992, 216:539-546.
42. Zell R., Geck P., Werdan K., Boekstegers P. TNFα and IL-1α inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Mol. Cell. Biochem. 1997, 177:61-67.
43. Zhang Z., Ding Y., Dai X., Wang J., Li Y. Epigallocatechin-3-gallate protects pro-inflammatory cytokine induced injuries in insulin-producing cells through the mitochondrial pathway. Eur. J. Pharmacol. 2011, 670:311-316.
44. Ji C., Chen X., Gao C., et al. IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes. J. Bioenerg. Biomembr. 2011, 43:367-375.
45. Tschopp J. Mitochondria: sovereign of inflammationα. Eur. J. Immunol. 2011, 41:1196-1202.
46. Lopez-Armada M., Riveiro-Naveira R., Vaamonde-Garcia C., Valcarcel-Ares M. Mitochondrial dysfunction and the inflammatory response. Mitochondrion 2013, 13:106-118.
47. Mihara M., Hashizume M., Yoshida H., Suzuki M., Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond.) 2012, 122:143-159.
48. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res. Ther. 2006, 8(Suppl. 2):S3.
49. Kaplanski G., Marin V., Montero-Julian F., Mantovani A., Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003, 24:25-29.
50. Nikolaisen C., Figenschau Y., Nossent J.C. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J. Rheumatol. 2008, 35:380-386.
51. Ripley B.J., Goncalves B., Isenberg D.A., Latchman D.S., Rahman A. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann. Rheum. Dis. 2005, 64:849-853.
52. Nachbaur D., Herold M., Maneschg A., Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann. Hematol. 1991, 62:54-58.
53. Maccio A., Madeddu C., Massa D., et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005, 106:362-367.
54. Leng S., Chaves P., Koenig K., Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J. Am. Geriatr. Soc. 2002, 50:1268-1271.
55. Nemeth E., Valore E.V., Territo M., et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003, 101:2461-2463.
56. Nemeth E., Rivera S., Gabayan V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004, 113:1271-1276.
57. Roy C. Anemia of inflammation. Hematol. Am. Soc. Hematol. Educ. Progr. 2010, 2010:276-280.
58. Nieken J., Mulder N.H., Buter J., et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood 1995, 86:900-905.
59. Atkins M.B., Kappler K., Mier J.W., Isaacs R.E., Berkman E.M. Interleukin-6-associated anemia: determination of the underlying mechanism. Blood 1995, 86:1288-1291.
60. Ferry A.E., Baliga S.B., Monteiro C., Pace B.S. Globin gene silencing in primary erythroid cultures. An inhibitory role for interleukin-6. J. Biol. Chem. 1997, 272:20030-20037.
61. Prince O.D., Langdon J.M., Layman A.J., et al. Late stage erythroid precursor production is impaired in mice with chronic inflammation. Haematologica 2012, 97:1648-1656.
62. Kitamura T., Tange T., Terasawa T., et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 1989, 140:323-334.
63. Chen K., Liu J., Heck S., et al. Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17413-17418.
64. Yuan J.S., Reed A., Chen F., Stewart C.N. Statistical analysis of real-time PCR data. BMC Bioinforma. 2006, 7:85.
65. Socolovsky M., Nam H., Fleming M.D., et al. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001, 98:3261-3273.
66. Wu F., Satchwell T.J., Toye A.M. Anion exchanger 1 in red blood cells and kidney: band 3's in a pod. Biochem. Cell Biol. 2011, 89:106-114.
67. Southcott M., Tanner M., Anstee D. The expression of human blood group antigens during erythropoiesis in a cell culture system. Blood 1999, 93:4425-4435.
68. Pendergrass W., Wolf N., Poot M. Efficacy of MitoTracker Green and CMXrosamine to measure changes in mitochondrial membrane potentials in living cells and tissues. Cytometry A 2004, 61:162-169.
69. Duchen M. Roles of mitochondria in health and disease. Diabetes 2004, 53:S96-S102.
70. Ehrenberg B., Montana V., Wei M., Wuskell J., Loew L. Membrane potential can be determined in individual cells from the nernstian distribution of cationic dyes. Biophys. J. 1988, 53:785-794.
71. Loew L., Carrington W., Tuft R., Fay F. Physiological cytosolic Ca2+ transients evoke concurrent mitochondrial depolarizations. PNAS 1994, 91:12579-12583.
72. Tsai W.H., Shih C.H., Yu Y.B., Hsu H.C. Plasma levels in sepsis patients of annexin A1, lipoxin A4, macrophage inflammatory protein-3a, and neutrophil gelatinase-associated lipocalin. J. Clin. Med. Assoc. 2013, 76(9):486-490.
73. Kado S., Nagase T., Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol. 1999, 36:67-72.
74. Pappa C.A., Tsirakis G., Psarakis F.E., et al. Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma. Med. Oncol. 2013, 30:363.
75. Fraqioudaki M., Boula A., Tsirakis G., et al. B cell-activating factor: its clinical significance in multiple myeloma patients. Ann. Hematol. 2012, 91:1413-1418.
76. Endo S., Aikawa N., Fujishima S., et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J. Infect. Chemother. 2008, 14:244-249.
77. Ando K., Kato H., Kotani T., et al. Plasma leukocyte cell-derived chemotaxin 2 is associated with the severity of systemic inflammation in patients with sepsis. Microbiol. Immunol. 2012, 56:708-718.
78. Oda S., Hirasawa H., Shiqa H., et al. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. Cytokine 2005, 29:169-175.
79. Paw B.H., Davidson A.J., Zhou Y., et al. Cell-specific mitotic defect and dyserythropoiesis associated with erythriod band 3 deficiency. Nat. Genet. 2003, 34:59-64.
80. Narendra D., Tanaka A., Suen D., Youle R. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008, 183:795-803.
81. Lange H., Kispal G., Lill R. Mechanism of iron transport to the site of heme synthesis inside yeast mitochondria. J. Biol. Chem. 1999, 274:18989-18996.
82. Santos N., Castilho R., Meinicke A., Hermes-Lima M. The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate. Eur. J. Pharmacol. 2001, 428:37-44.
83. Uchiyama A., Kim J., Kon K., et al. Translocation or iron from lysosomes into mitochondria is a key event during oxidative stress-induced hepatocellular injury. Hepatology 2008, 48:1644-1654.
84. Schipper H., Bernier L., Mehindate K., Frankel D. Mitochondrial iron sequestration in dopamine-challenged astroglia: role of heme oxygenase-1 and the permeability transition pore. J. Neurochem. 1999, 72:1802-1811.